The Aurora kinases represent a group of serine/threonine kinases which are crucial regulators of mitosis.
Introduction
AurkB is one of the three human paralogs of Aurora kinases and is a member of the chromosome passenger complex. It plays pivotal roles in chromosome congression, spindle bi-orientation and cytokinesis (Ruchaud S et al. 2007 ) and undergoes a multitude of post translational modifications which modulate its spatio-temporal behaviour necessary for proper mitotic progression (Monaco L et al. 2005; Ban R et al. 2011; Fernández-Miranda G et al. 2010; Catherine Lindon et al. 2016) . Although AurkB transcription or protein stability is tightly regulated prior to mitotic entry or following mitotic exit respectively (Kimura M et al. 2004; Park J et al. 2018) , this regulation is lost in cancer cells, leading to elevated steady state AurkB protein levels. It is frequently overexpressed in both solid and haematological malignancies, and is therefore a potential target of ani-neoplastic therapies (Borisa AC et al. 2017 ).
Proteome-wide high throughput studies have unveiled the "lysine acetylome" of a cell (Choudhary C et al. 2009 ). Interestingly, many cell cycle regulators were found to be acetylated. Congruently, histone deacetylase (HDAC) inhibitors were found to affect kinetochore assembly through decreased pericentromeric targeting of AurkB (Robbins AR et al. 2005) . HDAC3 was observed to not only assist in histone H3 deacetylation during mitosis to provide a hypoacetylated H3-tail for phosphorylation by AurkB (Li Y et al. 2006 ) but also deacetylate AurkB and enhance its kinase activity (Fadri-Moskwik M et al. 2012) . Additionally, AurkB interacts with class IIa histone deacetylases in determining their nuclear localization during mitosis (Guise AJ et al. 2012) .
We observe that p300 and Tip60 acetylate AurkB in vitro. Tip60 mediated acetylation of AurkB at two highly conserved K85 and K87 residues negatively influence its protein stability and kinase activity.
We propose that under normal physiology Tip60 mediated acetylation serves to contain AurkB oncogenicity. However, upon Tip60 downregulation, as observed in cancers (Gorrini C et al. 2007; Mattera L et al. 2009 ), AurkB is not only stabilized but also exhibit increase in its kinase activity, causing an overall increase in activity of the oncogenic kinase.
Materials and Methods

Cell culture, antibodies and reagents
HEK293 and HEK293T (purchased from ATCC), MDA-MB-231 and MCF7 were grown at 37°C in DMEM (Invitrogen, Thermo Fisher Scientific) containing 10% fetal bovine serum. To generate FlagAurkB overexpressing stable cell line, pCDH adenoviral vector containing N-terminal Flag-AurkB fusion was co-transfected with lentiviral gene containing plasmids (psPAX2, pRSV-Rev and pCMV-VSV-G) into HEK293T cells to package the mammalian clone into the viral particles. Forty-eight hours post-transfection, the generated viral particles were used to infect HEK293 cells, and subsequently sorted for the GFP-positive cell population. Constitutive Tip60 knockdown cell line and the corresponding control cell line were similarly established in HEK293 using Tip60 directed shRNA or a non-silencing shRNA cloned in pGIPZ vector (Dharmacon). Transient transfection of 2N3T-Tip60 or the corresponding control empty vector was carried out for 48 hours into HEK293 cells using Lipofectamine 2000 transfection reagent (Invitrogen); UV irradiation was carried out at a dose of 15mJ/cm 2 using Stratagene Stratalinker 1800; HEK293 cells overexpressing Flag-AurkB was treated with 10 µM of trichostatin A (TSA) (Sigma-Aldrich) or DMSO for 12 hours. Cells for the various treatments or transfection conditions were harvested by scraping and lysed in lysis buffer containing 50mM tris-HCl, pH 7.4, 150mM NaCl, 5mM EDTA, 1% NP40, and 1 X protease inhibitory cocktail (Sigma-Aldrich). Anti-Aurora kinase B antibody was purchased from Abcam; anti-Flag, anti-β-actin and anti-HA antibodies were purchased from Sigma-Aldrich; anti-tubulin antibody was purchased from Millipore.
Cycloheximide chase assay
3 X Flag pCMV10-AurkB WT or the corresponding acetylation defective (K85R-K87R) and mimetic (K85Q-K87Q) mutants were transiently transfected into HEK293 cells in 60mm dish format using Lipofectamine 2000. Twenty-four hours post transfection, the cells were trypsinized and re-seeded into 6 well-plate and allowed to grow for 24-36 hours more to grow till 60-70% confluence, after which they were treated with 150 µg/ml of cycloheximide (Sigma-Aldrich) for the indicated time periods. The cells were harvested by scraping and lysed in Laemmli buffer.
In vitro lysine acetyltransferase (KAT) assay
KAT assay was performed using highly purified, baculovirus-expressed, recombinant full-length lysine acetyltransferases-His6-Tip60, Flag-PCAF or His6-p300 from Sf21 insect cells as enzymes and His6-AurkB, as substrates, in a 30 μl final reaction volume. Briefly, the reaction mixture consisting of 50 mM tris-HCl, pH 8.0, 10% (v/v) glycerol, 1 mM dithiothreitol (DTT), 1 mM phenyl methyl sulfonyl fluoride (PMSF), 0.1 mM EDTA, pH 8.0, 10 mM sodium butyrate, and 1 μl of 3.3 Ci/mmol of H
-acetyl
Coenzyme A (acetyl-CoA) and the indicated proteins, was incubated at 30°C for 30 min. Mass acetylation was carried for 2.5 hours at 30°C (with replenishment of indicated enzymes and acetyl-CoA every 30 mins, thrice). To visualize the radiolabelled acetylated protein, the reaction products were resolved on 12% SDS-polyacrylamide gel upon electrophoresis and stained by coomassie brilliant blue (CBB) to ascertain the presence of proteins. The gel was then dehydrated in DMSO for 1hr and incubated with scintillation fluid (22.5% w/v PPO solution in DMSO) for 30 minutes and finally equilibrated in water for two hours. The rehydrated gel was dried using a gel drier and exposed to Xray film for 10-12 days.
In vitro kinase assay
Recombinant histone H3, expressed and purified from E. coli, was incubated with either mass acetylated (Tip60-mediated) or mock acetylated His6-Aurora kinase B, in a 30 µl reaction mixture containing 50 mM tris-HCl, 100 mM NaCl, 0.1 mM EGTA, 10 mM MgCl2, 0.2% β-mercaptoethanol and [γP32] ATP (Specific Activity 3.5 Ci/mmol). The reaction mixture was incubated at 30ºC for 15 minutes. The reaction was inhibited over ice for 5 minutes, constituent proteins were denatured by the addition of gel loading dye containing SDS, heated at 90ºC for 5 minutes and resolved using 12% denaturing PAGE, stained by CBB, and followed by autoradiography using X-ray films.
Results and Discussions
Tip60 acetylates AurkB at two highly conserved lysine residues
In order to identify the putative KAT(s) responsible for the lysine acetyltransferase activity toward AurkB, we adopted an unbiased approach and considered the screening of KATs belonging to three different families of lysine acetyltransferases, namely p300, PCAF and Tip60. Each of these enzymes were purified from Sf21 insect ovarian cells using suitable baculoviral constructs containing the human KAT homolog. Recombinant His6-AurkB, expressed and purified from E. coli was used for an in vitro lysine acetyltransferase (KAT) assay. It was intriguing to find that p300 and Tip60 were capable of acetylating AurkB, while PCAF could not (figure 1).
The haploinsufficient tumor suppressor, Tip60 is known to oppose oncogenesis. Factual downregulation of Tip60 expression in multiple cancer types and its direct involvement in acetylation dependent inhibition of oncogenic pathways (Du Z et al. 2010; Kim MY et al. 2007 ) led us to study the further possibility of a Tip60 dependent regulation of AurkB in the context of acetylation. In order to identify the acetylation sites, we performed in vitro mass acetylation of recombinant full length His6-AurkB using His6-Tip60. The acetylated protein was subjected to liquid chromatography-coupled tandem mass spectrometry (LC-MS/MS) and nine probable acetylated lysine residues were identified-K4, K31, K56, K85 (supplementary figure 1, panel-I), K87 (supplementary figure 1, panel-II) , K115, K168, K195, and K202. Additionally, we observed that K85 and K87 residues reside in a glycine-rich microenvironment and is part of a G-K-G-K motif, which is similar to G-K-X-G-K motif found in the well-studied Tip60 substrates-histone H4 and Twist ( figure 2A ). Noting the high extent of conservation of these two lysine residues (figure 2B), we mutated them, either singly or in combination, to arginine and the E. coli purified recombinant WT and mutant AurkB proteins were subjected to in vitro KAT assay. While the K85R-K87R double point mutant led to a complete abrogation of Tip60 mediated acetylation, the single point mutants were only minimally affected ( figure 2C ). The K85R-K87R mutant did not show any acetylation even for higher Tip60 concentrations ( figure 2D ), emphasizing these sites to be the major Tip60 mediated acetylation sites.
Tip60 and p300 may not possess overlapping acetylation sites on AurkB
The screening of different KATs had highlighted that p300, apart from Tip60, is also capable of acetylating AurkB in vitro. We subsequently studied the acetylation of K85 and K87 residues of AurkB by p300 and observed that p300 is capable of acetylating either of the individual point mutants-K85R
and K87R ( figure 3A) or the K85R-K87R double mutant ( figure 3B ). These results emphasize either the exclusivity of K85 and K87 residues toward Tip60 mediated acetylation or portrays the possibility of numerous p300 mediated acetylation sites on AurkB, and mutation of two (K85 and K87) amongst many, is incapable of altering the overall p300 dependent acetylation status of the AurkB protein.
Tip60 interacts with AurkB in cells
We studied if AurkB and Tip60 interact with each other in a cellular context. Reciprocal coimmunoprecipitation of ectopically overexpressed 2N3T-Tip60 (henceforth referred to as HA-Tip60) in HEK293 cells constitutively expressing Flag-AurkB confirmed their physical interaction ( figure 4 ).
These results demonstrate that Tip60 interacts with AurkB in cells and acetylate it at K85 and K87 residues.
Tip60 regulate protein levels of AurkB in cells
Histone deacetylases play important roles in mitosis. Broad and non-selective HDAC inhibitors like trichostatin A (TSA) inhibits class I HDACs (HDAC1, 3, 4, 6, and 10) and has been shown to induce . We also generated point mutants corresponding to acetylation defective (K85R-K87R) or mimetic (K85Q-K87Q) conditions, on Flag-AurkB mammalian expression vector, and observed that the later exhibited reduced stability under cycloheximide chase assay conditions ( figure 5D ). These observations collectively confirm that Tip60 mediated acetylation of AurkB at K85 and K87 residues result into its destabilization in cells.
We next asked if AurkB modulation agrees with a physiologically relevant scenario where Tip60 exhibits differential expression levels in cells. An earlier observation had demonstrated enhanced stabilization of Tip60 protein in cells upon UV exposure (Legube G et al. 2002) , owing to an inhibition of its degradation by MDM2. In agreement with this study, we observed that UV irradiation caused enhancement in Tip60 levels in cells and AurkB was concomitantly downregulated under such conditions ( figure 5E ).
Tip60 mediated acetylation inhibit the kinase activity of AurkB
K85 and K87 residues lie within the kinase domain of AurkB. This propelled us to study if the kinase activity is affected upon acetylation by Tip60. Recombinant His6-AurkB was acetylated in vitro with Tip60 and the acetylated kinase was used in an in vitro kinase assay with histone H3 as a substrate. We found that acetylation of AurkB lowered its kinase activity, when compared to the mock acetylated control (supplementary figure 3; figure 6A ). We extended our study in assessing the point mutants of
AurkB and observed that the acetylation mimetic K85Q-K87Q mutant exhibited reduced kinase activity as compared to either the WT or the acetylation defective K85R-K87R mutant ( figure 6B ). The acetylation defective mutant, however, showed higher kinase activity, even as compared to the WT kinase, the cause of which is presently unclear. These results confirm that Tip60 dependent acetylation inhibit the kinase activity of AurkB.
Discussion
AurkB is the catalytic component of the chromosomal passenger complex (CPC) and ensures proper chromosome alignment and segregation (Adams RR et al. 2001) . It also assists in cleavage furrow formation, and cytokinesis and hence a reduction in the kinase activity by either chemical inhibitors or RNA interference gives rise to chromosome segregation defects and aneuploidy (Ditchfield C et al. 2003; Hauf S et al. 2003) . AurkB overexpression in cultured mammalian cells and mouse model is reported to cause an increased tumor incidence by tetraploidization or inhibiting p53 and p21 levels and functions (Gully CP et al. 2012; González-Loyola A et al. 2015; Nguyen HG et al. 2009) or by modulation of Myc dependent tumors (den Hollander J et al. 2010; Yang D et al. 2010) . Furthermore, the paralogue-AurkA, has been reported to participate in varying signalling events which culminate into tumorigenesis and cancer progression (Katayama H et al. 2004; Briassouli P et al. 2007; Dar AA et al. 2009; Otto T et al. 2009 ).
Here, we report a previously unanticipated link between AurkB and Tip60 whereby Tip60 contributes to its tumor suppressive effects by not only inhibiting the kinase activity of AurkB but also through destabilization of the AurkB protein, through acetylation of two highly conserved lysine residues present in the kinase domain of AurkB. We propose that widespread Tip60 downregulation in cancers favour the deregulated increase in the overall activity of AurkB in tumor cells that may act as a causative factor for the associated alterations of p53 or c-Myc pathways. Furthermore, as earlier studies elucidate the direct links between Tip60 and genomic aberrations (Bassi C et al. 2016) , it is worthwhile to study if any of such effects are mediated by the altered activities of AurkB. Lesser extent of kinase activity was observed for the K85Q-K87Q mutant as compared to either the WT or the K85R-K87R mutant.
Supplementary figure 1. Mass spectra of K85 (panel-I) and K87 acetylation (panel-II).
